Teva launches generic Baraclude in the USA

4 September 2014

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) says it has launched its generic equivalent to Baraclude (entecavir) tablets, 0.5mg and 1mg, in the USA.

Teva says it was the first to file for US regulatory approval for its copy product, making it eligible for 180 days of marketing exclusivity.

Baraclude, marketed by US pharma major Bristol-Myers Squibb (NYSE: BMY) as a treatment for hepatitis, had annual sales of about $328 million in the USA, according to IMS data as of June 2014 quoted by Teva.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK